MindMed

MindMed to Present at Upcoming April Medical Conferences

Retrieved on: 
Tuesday, April 2, 2024
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Medicine, COVID, MindMed, Epidemiology

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:

MindMed Announces Voluntary Delisting from Cboe Canada

Retrieved on: 
Monday, April 1, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Medicine, MindMed, FAQ

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada.
  • The board of directors of the Company has approved the voluntary delisting from Cboe Canada.
  • In accordance with the Cboe Canada Listing Manual, Cboe Canada does not require shareholder approval of the voluntary delisting of MindMed’s common shares, as an acceptable alternative market will exist for the common shares on the date of delisting.
  • MindMed will continue to be a reporting issuer under applicable securities laws in all provinces and territories of Canada following the delisting of the common shares from Cboe Canada.

MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference

Retrieved on: 
Monday, March 11, 2024
Alternative Medicine, Mental Health, Health, Clinical Trials, Pharmaceutical, Biotechnology, SVB Securities, Medicine, Conference, MindMed

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024.

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

Retrieved on: 
Thursday, March 7, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Anxiety, Week, Doctor of Philosophy, MD, MindMed, FDA, GAD, University, Patient, Psychiatry, Medicine, Pharmaceutical industry

The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.

Key Points: 
  • The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.
  • MM120 was administered as a single dose in a monitored clinical setting with no additional therapeutic intervention.
  • “I’ve conducted clinical research studies in psychiatry for over two decades and have seen studies of many drugs under development for the treatment of anxiety.
  • MindMed management will host a webcast at 8:00 am ET today to discuss the Phase 2b results of MM120 in GAD.

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Thursday, March 7, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Janus, Attention, Prospectus, Medicine, Capital market, MindMed, Telephone, RBC Capital Markets, File, Cantor, Sale, Form, Richard Driehaus, State Street, SVB Securities, Security (finance)

In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.

Key Points: 
  • In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.
  • Gross proceeds to MindMed from the underwritten offering and concurrent private placement, before deducting underwriting commissions, placement agent fees and other offering-related expenses, are expected to be approximately $175 million.
  • Leerink Partners and Cantor are acting as joint bookrunning managers for the underwritten offering and placement agents for the private placement.
  • RBC Capital Markets is acting as lead manager for the underwritten offering and placement agent for the private placement.

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

Retrieved on: 
Friday, March 1, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, GAD, ODT, MindMed, Webcast, Medicine

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024.
  • The event will begin at 8:00 a.m. Eastern Time on Thursday, March 7, 2024.
  • The webcast and slides will be accessible live under “News & Events” on the Investors page of the Company’s website at https://ir.mindmed.co/ or by clicking here .
  • A replay of the event will be available on MindMed’s website.

MindMed Reports 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Senior, Week, ODT, MindMed, FDA, University Hospital of Basel, DSM-IV codes, Standard of care, GAD, Patient, Anxiety, Medicine, Pharmaceutical industry

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.
  • “2023 was a highly productive year for MindMed, which concluded with positive Phase 2b results for MM120 in the treatment of adult patients with GAD,” said Rob Barrow, Chief Executive Officer and Director of the Company.
  • As of December 31, 2023, MindMed had cash and cash equivalents totaling $99.7 million compared to $142.1 million as of December 31, 2022.
  • MindMed management will host a conference call at 8:00 AM EST today to provide a corporate update and review the Company’s 2023 financial results.

MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, Health, Webcast, Medicine, MindMed

ET to provide a corporate update and review the Company’s results for the year ended December 31, 2023.

Key Points: 
  • ET to provide a corporate update and review the Company’s results for the year ended December 31, 2023.
  • Listeners can register for the webcast via this link .
  • A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/ , and archived for at least 30 days after the webcast.
  • Those who plan on participating are advised to join 15 minutes prior to the start time.

Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder

Retrieved on: 
Friday, March 8, 2024
Anxiety, Research, MindMed, FDA, TSX, GAD, Clinical trial, Psychotherapy, Pharmaceutical industry

Based on initial clinical data from the Phase 2b trial and the significant unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has designated MM120 for GAD as a breakthrough therapy.

Key Points: 
  • Based on initial clinical data from the Phase 2b trial and the significant unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has designated MM120 for GAD as a breakthrough therapy.
  • Numinus' Cedar Clinical Research Draper Utah research clinic was among the highest enrolling sites for the study, with its clinic at Murray, Utah, also participating.
  • Dr. Reid Robison, Numinus' Chief Clinical Officer and Dr. Paul Thielking, Chief Science Officer, were Principal Investigators.
  • "We look forward to continuing to work with MindMed as it advances its important research into MM120.

MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference

Retrieved on: 
Wednesday, February 7, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, MindMed, Conference, Medicine

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference: